Probability of overall survival of all de novo AML patients (A) and those less than 60 years of age (B) according to Kaplan-Meier calculation in relation to wt1 mRNA (no or weak v intermediate or strong) expression at the time of diagnosis. Patients undergoing allogeneic BMT were censored at the time of BMT.